anti-Claudin-18.2 monoclonal antibody (Integral Molecular)

N/A

Report date: 2025/03/14 16:51:40

Base Information

Drug Nameanti-Claudin-18.2 monoclonal antibody (Integral Molecular)
Drug Alias Nameanti-CLDN18.2 mAb (Integral Molecular)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionClaudin-18 splice variant 2 antagonists
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A